Kurs & Likviditet
Beskrivning
Land | Norge |
---|---|
Lista | OB Match |
Sektor | Hälsovård |
Industri | Bioteknik |
2022-06-15 15:54:12
Oslo, Norway, June 15, 2022 - Nykode Therapeutics ASA (Euronext Growth Oslo:
NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and
development of vaccines and novel immunotherapies, today announced further
updates regarding it stock exchange uplisting process.
Reference is made to the announcement by Oslo Stock Exchange on June 13, 2022,
regarding the approval of the transfer of listing of the shares in Nykode
Therapeutics ASA from trading on Euronext Growth Oslo to the Oslo Stock
Exchange's main list.
The first day of trading of the Company's shares on the Oslo Stock Exchange's
main list is expected to be on or about June 16, 2022. Consequently, the last
day of trading of the Company's shares on Euronext Growth Oslo is expected to be
today, June 15, 2022.
The Company has prepared a prospectus in connection with the listing of its
shares on the Oslo Stock Exchange's main list. The prospectus was approved by
the Norwegian Financial Supervisory Authority today, June 15, 2022, and will be
available at the Company's web page from June 16, 2022 at 8.00 a.m. CET at
www.nykode.com/investors/financial-reports-and-presentations.
About Nykode Therapeutics
Nykode Therapeutics is a clinical-stage biopharmaceutical company dedicated to
the discovery and development of vaccines and novel immunotherapies for the
treatment of cancer and infectious diseases. Nykode's modular vaccine technology
specifically targets antigens to Antigen Presenting Cells, which are essential
for inducing rapid, strong and long-lasting antigen specific immune responses
and eliciting efficacious clinical responses.
Nykode's lead product candidates are VB10.16, a therapeutic vaccine for the
treatment of human papilloma virus (HPV)-16 induced malignancies which
demonstrated positive interim efficacy and safety results from its Phase II
trial for the treatment of cervical cancer